Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 15;96(3):234-8.
doi: 10.1097/TP.0b013e318298f9fa.

Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials

Marcella Franquesa  1 , Martin J Hoogduijn, Marlies E Reinders, Elke Eggenhofer, Anja U Engela, Fane K Mensah, Joan Torras, Antonello Pileggi, Cees van Kooten, Bernard Mahon, Oliver Detry, Felix C Popp, Volker Benseler, Federica Casiraghi, Christian Johnson, Janis Ancans, Barbara Fillenberg, Olga delaRosa, Josep M Aran, Marieke Roemeling-van Rhijn, Jef Pinxteren, Norberto Perico, Eliana Gotti, Bruno Christ, James Reading, Martino Introna, Robert Deans, Murat Shagidulin, Ramon Farré, Alessandro Rambaldi, Albert Sanchez-Fueyo, Natasha Obermajer, Andrey Pulin, Frank J M F Dor, Isabel Portero-Sanchez, Carla C Baan, Ton J Rabelink, Giuseppe Remuzzi, Michiel G H Betjes, Marc H Dahlke, Josep M Grinyó; MiSOT Study Group
Affiliations

Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials

Marcella Franquesa et al. Transplantation. .

Erratum in

  • Transplantation. 2013 Sep;96(6):e49. Roemeling-vanRhijn, Marieke [corrected to Roemeling-van Rhijn, Marieke]

Abstract

The Fourth Expert Meeting of the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Consortium took place in Barcelona on October 19 and 20, 2012. This meeting focused on the translation of preclinical data into early clinical settings. This position paper highlights the main topics explored on the safety and efficacy of mesenchymal stem cells as a therapeutic agent in solid organ transplantation and emphasizes the issues (proper timing, concomitant immunossupression, source and immunogenicity of mesenchymal stem cells, and oncogenicity) that have been addressed and will be followed up by the MiSOT Consortium in future studies.

PubMed Disclaimer

References

    1. Dahlke MH, Hoogduijn M, Eggenhofer E, et al. Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation. 2009;88 (5):614. - PubMed
    1. Hoogduijn MJ, Popp FC, Grohnert A, et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT) Transplantation. 2010;90 (2):124. - PubMed
    1. Perico N, Casiraghi F, Introna M, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6 (2):412. - PMC - PubMed
    1. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012;307 (11):1169. - PubMed
    1. Reinders ME, de Fijter JW, Roelofs H, et al. Autologous Bone Marrow-Derived Mesenchymal Stromal Cells for the Treatment of Allograft Rejection After Renal Transplantation: Results of a Phase I Study. Stem Cells Transl Med. 2013 - PMC - PubMed

Publication types

MeSH terms